New pancreatic cancer drug might open the door to much longer survival times

Therapy and Mechanism

• Discussion centers on daraxonrasib, a drug targeting cancers with KRAS mutations, previously seen as “undruggable.”
• Instead of blocking KRAS directly, it “glues” KRAS to another protein (CypA), sequestering it away from where it drives growth.
• Posters note this represents a new drug modality (molecular glues / protein–protein interaction manipulators), potentially opening many future therapies.

Clinical Scope and Trials

• The article’s “master switch” framing is called hyperbolic; commenters stress it likely applies to ~20% of tumors, though many of these are among the hardest-to-treat cancers.
• Current data come from pancreatic cancer patients who failed first-line therapy; survival gains are measured in months on average, not years, but still viewed as meaningful.
• Multiple clinical trials are underway: second-line and first-line pancreatic cancer, lung cancer, and combinations with other drugs; more trials are expected.
• One comment claims the drug has passed phase 3 trials and that there is an access trial to broaden availability.
• Side effects are described as “horrible,” and learning how to manage them is seen as a major next step.

Cancer Complexity and Resistance

• Repeated emphasis that “cancer is not one thing”; different cancers and even regions of a single tumor can behave differently.
• Comparisons to antibiotics and penicillin are discussed; consensus is that a universal “cure for cancer” is unlikely due to heterogeneity and rapid evolution within tumors.
• Drug resistance and evolutionary pressure under therapy are highlighted as central challenges.

Debate on Value of Incremental Gains

• Some express cynicism that non-curative drugs merely prolong dependence and profit; others strongly counter that even months or a few extra years—especially in aggressive cancers—are profound wins for patients and families.
• Clinical trial participants are widely portrayed as crucial to progress, though there is disagreement on how much to celebrate incremental benefits.

Diet, Metabolism, and Anecdotes

• One detailed anecdote describes combining chemotherapy and surgery for pancreatic cancer with a strict diet: eliminating sugar and animal products, guided by cancer’s reliance on glucose and glutamine.
• The reported outcome: major tumor shrinkage, normalization of markers, good tolerance of chemo, and long-term cancer-free status, with relapse of markers when diet relaxed.
• Others caution that such cases are anecdotal; without randomized controlled trials, dietary recommendations may help or harm and should not be treated as proven therapy.
• There is brief mention of experimental “starving cancer” strategies (ketogenic diets plus drugs targeting glutamine), but only as exploratory ideas.

Alternative Research Directions

• Michael Levin’s work on bioelectric signaling and its potential to start/stop cancer or drive regeneration via voltage patterns is mentioned as intriguing but still largely in early-stage and needing in vivo human results to gain traction.
• Another thread on CRISPR-based cancer treatments is referenced as part of a broader landscape of parallel breakthroughs.

Science Funding and Politics

• Several comments warn that US science and NIH funding are under political threat, with claims of slowed grant awards, politicized control of funding, restrictions on international collaboration, and greater uncertainty.
• Others argue for cutting perceived bureaucratic or politically driven parts of the system, claiming favoritism in hiring and funding; critics respond that these claims lack evidence and that cuts are already harming core research.
• Broader concern is expressed that undermining scientific infrastructure will slow exactly the kinds of advances represented by drugs like daraxonrasib.

Meta and Broader Implications

• Many see this result as an important “baby step”: the first real hit on KRAS plus proof that previously “undruggable” targets can be tackled.
• There is cautious optimism that AI and new drug design tools may accelerate similar breakthroughs in cancer and other diseases.